Suven Life gets product patents from New Zealand, Norway

| Updated on May 22, 2018 Published on May 22, 2018

Suven Life Sciences on Tuesday said that it has been granted one product patent each from New Zealand and Norway corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034 and 2027, respectively.

The granted claims of the patents include the class of selective 5HT6 compounds and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficient hyperactivity disorder, Huntington’s disease, Parkinson’s and schizophrenia, respectively. Shares of Suven Life jumped 4.6 per cent at ₹188.75 on the BSE.

Published on May 22, 2018
This article is closed for comments.
Please Email the Editor